Market Overview

UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Gilead Sciences

Related GILD
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Bristol-Myers Seeks Approval for HIV Combo Drug - Analyst Blog
Don't Panic Over Recent Tech Turmoil (Fox Business)

In a report published Wednesday, Deutsche Bank reiterated its Buy rating on Gilead Sciences (NASDAQ: GILD), but lowered its price target from $95.00 to $48.00.

Deutsche Bank noted, “We are updating our TP and EPS estimates for Gilead's recent 2:1 stock split. Our new TP is $48 & our pre-split TP was $95. Our new 4Q12, FY 2012 and 2013 non-GAAP EPS estimates are $.51, $1.98, and $2.35 respectively. New 4Q12 fully diluted share count is 1582 with average share count of 1568 for FY 2012. We have made no changes to our revenue projections or expenses. Our thesis remains unchanged on HCV & HIV.”

Gilead Sciences closed on Tuesday at $39.90.

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (GILD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free